Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 7/20 | 0.56 |
| ▸ | EGFR | P00533 | 6/20 | 0.51 |
| ▸ | RET | P07949 | 1/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16962336 | 0.91 | MKNK1 (0.53) | MKNK1EGFRRETS1PR1 | |
| SCHEMBL16963568 | 0.91 | MKNK1 (0.58) | MKNK1EGFRRETERBB2S1PR1 | |
| SCHEMBL16963619 | 0.90 | MKNK1 (0.48) | MKNK1EGFRRET | |
| SCHEMBL16962040 | 0.83 | MKNK1 (0.67) | MKNK1EGFRRETERBB2 | |
| SCHEMBL16963123 | 0.83 | MKNK1 (0.58) | MKNK1EGFRRETERBB2TP53 | |
| SCHEMBL16963088 | 0.82 | MKNK1 (0.61) | MKNK1EGFRRETERBB2 | |
| SCHEMBL16963343 | 0.80 | MKNK1 (0.65) | MKNK1EGFRRETERBB2 | |
| SCHEMBL16963262 | 0.79 | ROCK2 (0.59) | MKNK1EGFRRET | |
| SCHEMBL7495904 | 0.79 | ALOX15 (0.49) | EGFRERBB2 | |
| SCHEMBL16963547 | 0.77 | MKNK1 (0.62) | MKNK1EGFRRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150218173-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERFOLIFERATIVE DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-06 | — | — | US | disclosed |
| US-20150218173-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERFOLIFERATIVE DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-06 | — | — | US | disclosed |
| EP-2900670-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERFOLIFERATIVE DISORDERS | Bayer Pharma Aktiengesellschaft (DE) | 2015-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218173-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERFOLIFERATIVE DISORDERS | CCND2, ARG2, ARG1 | MKNK1 2957/4885EGFR 3423/4885RET 1426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.